TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
TBCRC 035：一项随机 II 期药效学研究，评估标准剂量和减量帕博西尼联合内分泌治疗在激素受体 (HR) 阳性、既往接受过治疗的转移性乳腺癌患者中的疗效
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106063
Jacob, S; Mayer, E L; Kacik, N; Storniolo, A M; Isaacs, C; Mayer, I; Stearns, V; Nanda, R; Nangia, J; Chien, A J; Moasser, M; Melisko, M; Wabl, C; Muzikansky, A; Geradts, J; Dillon, D A; Park, B H; Krop, I; Wolff, A C; Kochupurakkal, B; Shapiro, G I; Rugo, H S
